Online inquiry

IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4398MR)

This product GTTS-WQ4398MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD80&CD86 gene. The antibody can be applied in Kidney transplant rejection research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005191.4; NM_001206924.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 941; 942
UniProt ID A0N0P2; P42081
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ4398MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ11656MR IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MHAA4549A
GTTS-WQ9698MR IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64304500
GTTS-WQ3275MR IVTScrip™ mRNA-Anti-alpha toxin&<br />lukE, ASN-1(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ASN-1
GTTS-WQ5574MR IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CDP-771
GTTS-WQ5244MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CB-6
GTTS-WQ1820MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AFD Anti-fD
GTTS-WQ12936MR IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PankoMab
GTTS-WQ5767MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CetuxiMab-GEX
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW